WO2025108284 - COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SODIUM VOLTAGE-GATED CHANNEL ALPHA SUBUNIT 9 (SCN9A)

National phase entry:
Publication Number WO/2025/108284
Publication Date 30.05.2025
International Application No. PCT/CN2024/133074
International Filing Date 20.11.2024
Title **
[English] COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF SODIUM VOLTAGE-GATED CHANNEL ALPHA SUBUNIT 9 (SCN9A)
[French] COMPOSITIONS ET PROCÉDÉS D'INHIBITION DE L'EXPRESSION DE LA SOUS-UNITÉ 9 DU CANAL SODIQUE VOLTAGE-DÉPENDANT (SCN9A)
Applicants **
SHANGHAI ARGO BIOPHARMACEUTICAL CO., LTD.
Inventors
SHU, Dongxu
SHAO, Pengcheng Patrick
XIA, Shiwei
Priority Data
PCT/CN2023/132649   20.11.2023   CN
PCT/CN2024/122315   29.09.2024   CN
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting4712
EPO Filing, Examination, Granting69294
Japan Filing, Examination, Granting4097
South Korea Filing, Examination, Granting6336
USA Filing, Examination, Granting22040
MasterCard Visa
Total: 106,479

The term for entry into the National Phase has expired. This quotation is for informational purposes only

Contact Us
Abstract[English] Compositions and methods useful to reduce expression of sodium voltage-gated channel alpha subunit 9 (SCN9A) gene and for treatment of SCN9A-associated diseases and conditions are provided. Provided are SCN9A dsRNA agents, SCN9A antisense polynucleotide agents, compositions comprising SCN9A dsRNA agents, and compositions comprising SCN9A antisense polynucleotide agents that can be used to reduce SCN9A expression in cells and subjects.[French] L'invention concerne des compositions et des procédés utiles pour réduire l'expression du gène de la sous-unité 9 du canal sodique voltage-dépendant (SCN9A) et pour le traitement de maladies et d'états associés à SCN9A. L'invention concerne des agents ARNdb SCN9A, des agents polynucléotidiques antisens SCN9A, des compositions comprenant des agents ARNdb SCN9A, et des compositions comprenant des agents polynucléotidiques antisens SCN9A qui peuvent être utilisés pour réduire l'expression de SCN9A dans des cellules et chez des sujets.